Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Corsica Health vs myRocky

Corsica Health
Graded #188

Higher grade

vs+14.899999999999999
myRocky
Graded #487

Lower grade

The verdict

Corsica Health takes it — 66.3/100 to 51.4/100.

Corsica Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Corsica Health is a telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections through a structured assessment, provider review, and medication flow.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCorsica Health +14
48
34
Dose & formulationCorsica Health +24
77
53
Clinical oversightCorsica Health +23
87
64
Labs & monitoringCorsica Health +2
54
52
FulfillmentCorsica Health +5
75
70
Contract termsCorsica Health +14
55
41
Corsica Health · left barmyRocky · right bar

The numbers

MetricCorsica HealthmyRocky
WeighScore66.3/10051.4/100
GradeCC
Scorecard rank#188#487
Semaglutide$249/mo (compounded)Not disclosed
Tirzepatide$349/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Corsica Health

Graded #188 · C

Strengths

  • Public pricing shown for both compounded and brand-name options — a real transparency advantage
  • $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
  • LegitScript Certified
  • Clear 3-step intake: Assessment, Provider Review, Receive Medication
  • $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced

Where it loses points

  • Legal entity name and state of incorporation not disclosed on the site
  • Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
  • Per-state availability not listed publicly
  • First-month promotional pricing not disclosed
  • Lab-work inclusion not clearly disclosed
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard